Marksans Pharma Posts Record Q2FY27 Results With 48% EBITDA Surge
Marksans Pharma Ltd 路 Press Release 路 04 Nov 2026, 7:12 pm
Marksans Pharma Posts Record Q2FY27 Results With 48% EBITDA Surge Marksans Pharma reported a 30.5% YoY rise in consolidated operating revenue to Rs. 940.2 cr in Q2FY27, driven by strong growth in UK & Europe (+64.9% YoY to Rs. 404.6 cr) and the US (+8.7% YoY to Rs. 420.9 cr). EBITDA grew 48.3% YoY to Rs. 214.3 cr with margins expanding 274 bps to 22.8%. PAT rose 44.8% YoY to Rs. 143.5 cr. In H1FY27, PAT surged 92.5% YoY to Rs. 302.9 cr, operating cash flow jumped 4.3x to Rs. 322 cr, and net cash stood at Rs. 1,095 cr.
Original exchange filing (PDF)
More announcements from Marksans Pharma Ltd
- Transcript of Investors/Analyst meet on Q2 FY27 Financial Results 路 13 Nov 2026
- Audio Recording of investor(s)/analyst(s) meet Conference Call on Q2 FY 27 Financial Results 路 05 Nov 2026
- Allotment of Equity Shares under Marksans Employees Stock Option Scheme 2024 路 04 Nov 2026
- Investor Presentation Q2FY27 路 04 Nov 2026
- Unaudited Standalone and Consolidated Financial Results for the quarter and half year ended 30 September 2026 路 04 Nov 2026
- Marksans Pharma Limited has submitted to the Exchange, unaudited financial results for the quarter and half year ended September 30, 2026. 路 04 Nov 2026
- Please find attached outcome of the Board meeting held on 04 November 2026 路 04 Nov 2026
- Intimation of schedule for Q2FY27 Earnings Conference Call 路 05 Nov 2026
